Tempest Therapeutics, Inc.TPSTNASDAQ
Loading
EV/EBITDA Over TimeExpanding
Percentile Rank46
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Percentile
P46
Within normal range
vs 3Y Ago
-14.3x
Contraction
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
2024-7.17+77.0%
2023-31.21-24998.4%
2022-0.12-124.9%
20210.50+173.8%
20200.18+100.7%
2019-26.24-713.6%
2018-3.23-2778.2%
20170.12+101.6%
2016-7.46+84.2%
2015-47.24-